Fig. 3From: Financing repurposed drugs for rare diseases: a case study of Unravel BiosciencesResults of the Monte Carlo simulation model for the portfolio of orphan drug compounds (right column) and for a single drug compound (left column) using a discount rate of \(r=13\%\). We present the overall NPV of the project, as well as the NPV in year 0 of selling the project in phase 2 and in phase 3Back to article page